Cytokinetics Inc (NASDAQ: CYTK) is -16.03% lower on its value in year-to-date trading and has touched a low of $25.98 and a high of $110.25 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $71.41 in the last trading session, with the day’s loss setting it -1.3%.
Currently trading at $70.11, the stock is 4.27% and -6.06% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.61 million and changing -1.82% at the moment leaves the stock 47.37% off its SMA200. CYTK registered 100.43% gain for a year compared to 6-month gain of 134.32%. The firm has a 50-day simple moving average (SMA 50) of $977.77 and a 200-day simple moving average (SMA200) of -$16.12.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -4.08% loss in the last 1 month and extending the period to 3 months gives it a -15.98%, and is 6.18% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.94% over the week and 5.12% over the month.
Cytokinetics Inc (CYTK) has around 423 employees, a market worth around $7.22B and $7.53M in sales. Profit margin for the company is -6988.63%. Distance from 52-week low is 169.86% and -36.41% from its 52-week high. The company has generated returns on investments over the last 12 months (-154.11%).
Cytokinetics Inc quarterly earnings per share for the current quarter are estimated at -$1.14 with sales reaching $970k over the same period.The EPS is expected to grow by 18.14% this year, but quarterly earnings will post -14.90% year-over-year. Quarterly sales are estimated to shrink -79.00% in year-over-year returns.
Cytokinetics Inc (CYTK) Top Institutional Holders
465 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 114.83% of the company’s shares. The shares outstanding are 101.64M, and float is at 99.23M with Short Float at 14.91%. Institutions hold 113.82% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 15.36 million shares valued at $501.11 million. The investor’s holdings represent 16.00% of the CYTK Shares outstanding. As of Jun 29, 2023, the second largest holder is FMR, LLC with 12.16 million shares valued at $396.76 million to account for 12.67% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 10.27 million shares representing 10.70% and valued at over $335.03 million, while Wellington Management Group, LLP holds 8.62% of the shares totaling 8.27 million with a market value of $269.79 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Malik Fady Ibraham,the company’sEVP Research & Development. SEC filings show that Malik Fady Ibraham sold 32,604 shares of the company’s common stock on Mar 05 ’24 at a price of $67.56 per share for a total of $2.2 million. Following the sale, the insider now owns 0.14 million shares.
Cytokinetics Inc disclosed in a document filed with the SEC on Feb 14 ’24 that HENDERSON JOHN T (Director) sold a total of 5,000 shares of the company’s common stock. The trade occurred on Feb 14 ’24 and was made at $76.48 per share for $0.38 million. Following the transaction, the insider now directly holds 42632.0 shares of the CYTK stock.
Still, SEC filings show that on Feb 13 ’24, Blum Robert I (President & CEO) disposed off 12,500 shares at an average price of $76.85 for $0.96 million. The insider now directly holds 441,797 shares of Cytokinetics Inc (CYTK).
